Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4213728

O=C(O)C(F)(F)F.O=C(O)c1ccc(-c2ccccc2)cc1Nc1cccc2cnccc12

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ACLY P53396 2/20 0.45
▸ TRPV1 Q8NER1 12/20 0.45
▸ KDM4C Q9H3R0 2/20 0.45
▸ PDE4B Q07343 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ KDM5B Q9UGL1 1/20 0.42
▸ CDC25B P30305 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ BLM P54132 1/20 0.42
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4226821 0.94 KDM4C (0.50) ACLYTRPV1KDM4CPDE4BKDM5B
Trifluoroacetic Acid SCHEMBL4222841 0.88 ACLY (0.45) ACLYKDM4CKDM5BCDC25B
SCHEMBL4213733 0.86 TRPV1 (0.45) TRPV1PDE4BKDM4EALDH1A1MAPT
Trifluoroacetic Acid SCHEMBL4218730 0.85 TRPV1 (0.51) TRPV1KDM4CKDM4EALDH1A1MAPT
SCHEMBL4209243 0.81 ACLY (0.49) ACLYKDM4CKDM5BCDC25B
SCHEMBL4210974 0.78 TRPV1 (0.56) TRPV1KDM4CKDM4EALDH1A1MAPT
SCHEMBL21999614 0.76 ACLY (0.61) ACLY
Trifluoroacetic Acid SCHEMBL4225801 0.74 PAX8 (0.47) ACLYKDM4ESMN1; SMN2
SCHEMBL4222846 0.74 MAP3K8 (0.38) ACLYTRPV1PDE4BCDC25B
SCHEMBL4215643 0.73 MAPT (0.52) ACLYKDM4EALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 — — US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 — — EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 — — US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 ACLY 430/4885TRPV1 3589/4885KDM4C 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback